Status:
UNKNOWN
PCI and Renal Denervation in Hypertensive Patients With Acute Coronary Syndromes
Lead Sponsor:
Sahlgrenska University Hospital
Conditions:
Hypertension
Acute Myocardial Infarction
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
Research hypothesis: Is the treatment with renal denervation (RDN) early post ACS safe and effective and does it leads to improved cardiac function and attenuation of pathologic left ventricular remo...
Detailed Description
The sympathetic nervous system plays a crucial role in the development and progression of hypertension and its adverse consequences. Despite the availability of numerous effective pharmacologic treatm...
Eligibility Criteria
Inclusion
- Provision of informed consent prior to any study specific procedures
- Female and/or male aged 18-80 years
- Patients with ACS, i.e. STEMI, non-STEMI, treated with PCI
- Medical history of treated (ongoing) hypertension, or hypertension discovered at the time of ACS, and office SBP \>140 despite treatment with three antihypertensive drugs.
- Ejection fraction \>40%.
Exclusion
- Increased risk of pathological bleedings
- Office systolic blood pressure \<120
- Renal artery abnormalities.
- eGFR \<30 mL/min
- ICD or pacemaker, or any other metallic implant not compatible with MRI
- Estimated survival time \<1 year
- Not oriented to person, place and time
- Inability to understand given information about the study
- Fertile female
Key Trial Info
Start Date :
October 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2016
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT02272920
Start Date
October 1 2014
End Date
March 1 2016
Last Update
October 24 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sahlgrenska University Hospital
Gothenburg, Sweden, 41345